GSK’s Blenrep Returns With Simpler REMS, But Narrower Indication Than Targeted

 
• By Andrew McConaghie
  
GSK
Administration outside the hospital is one of Blenrep's advantages in the market, GSK said.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

More from United States